1. Pink Sheet
  2. >>Market Access

Opening A Window: Algeta Must Find Xofigo’s Place In The Prostate Cancer Market

 
• By Jessica Merrill

Bayer/Algeta’s Xofigo was cleared for castration-resistant prostate cancer patients with symptomatic bone metastases, but uptake of the radiotherapeutic will require referrals from most providers to a licensed radiation site and the company must find a way for the drug to be used instead of or in sequence with chemo and other prostate cancer therapies.

The need for Bayer AG/Algeta ASA’s prostate cancer radiotherapeutic Xofigo (radium Ra 223 dichloride) to be administered at a licensed site could pose access issues that could impact the speed of the launch.

FDA approved Xofigo May 15 for the treatment of castration-resistant prostate cancer in patients with symptomatic bone metastases, a critically ill subset that gives Bayer and Algeta a more specific target than Johnson & Johnson’s Zytiga (abiraterone acetate) and

More from Pricing Debate

More from Market Access